Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Melody Wilkinson

Nurse Practitioner, Adult Health Warm Springs, MT Nurse Practitioner

NPI 1225798473 CMS profile 11357671

300 Garnet Way, Warm Springs, MT 59756

Open in the dashboard

General payments

$1,415

83 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melody Wilkinson of Warm Springs, MT is reported in the CMS Open Payments database as having received $1,415 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 2
2023 General $1,110 62
2022 General $271 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melody Wilkinson
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Melody Wilkinson were reported at $33. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Melody Wilkinson Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $138 $43–$438 $132
2022 $271 $165 $54–$494 $149
2023 $1,110 $178 $61–$549 $160
2024 $0 $186 $62–$575 $164
2025 $33 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $360 16 payments
  2. AstraZeneca Pharmaceuticals LP $207 10 payments
  3. Novartis Pharmaceuticals Corporation $145 12 payments
  4. Dexcom, Inc. $108 7 payments
  5. Otsuka America Pharmaceutical, Inc. $103 7 payments
  6. Pfizer Inc. $97 6 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $96 6 payments
  8. Lilly USA, LLC $83 5 payments
  9. Abbott Laboratories $59 4 payments
  10. Novo Nordisk Inc $32 2 payments
  11. Other $124 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,415 83 payments
Products named General payments · program years 2022–2025
  1. UBRELVY $280 12 payments
  2. QULIPTA $229 7 payments
  3. BREZTRI $189 9 payments
  4. LEQVIO $128 11 payments
  5. Dexcom G6 Transmitter $108 7 payments
  6. REXULTI $103 7 payments
  7. PAXLOVID $97 6 payments
  8. MOUNJARO $83 5 payments
  9. ENTRESTO $81 8 payments
  10. NURTEC ODT $80 5 payments
  11. Other $574 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

842

Median for Nurse Practitioner: 389

Drug cost

$23,267

Median for Nurse Practitioner: $21,885

Branded share of claims

23%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 30 $13,591
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $1,657
Levothyroxine Sodium Generic 91 $836
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $724
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $659
Potassium Chloride Generic 24 $614
Atorvastatin Calcium Generic 74 $462
Pantoprazole Sodium Generic 44 $393
Celecoxib Generic 11 $390
Ventolin Hfa Albuterol Sulfate Brand 11 $350

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record